PAG
BCRX icon

Private Advisor Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Private Advisor Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,400
Closed -$11K – 1744
2020
Q2 		$11K Buy
+2,400
New +$9.59K ﹤0.01% 2876

Other funds holding BCRX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Private Advisor Group's BCRX Position: Q3 2020 in Review

Private Advisor Group sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2020, closing a stake of 2,400 shares — an estimated $11K sold.

Private Advisor Group first reported a position in BCRX in Q2 2020 and held it in 1 quarter. The position peaked at $11K in Q2 2020. 154 funds tracked by Wall St. Rank hold BCRX as of Q3 2020.

  • Private Advisor Group reported no remaining BioCryst Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 2,400 BioCryst Pharmaceuticals shares in Q3 2020, an estimated $11K.
  • Private Advisor Group first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's BioCryst Pharmaceuticals position peaked at $11K in Q2 2020.
  • 154 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.